Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
BioSpace
The approval of Ionis Pharmaceuticals' Tryngolza for severe hypertriglyceridemia could spur "substantial growth" for the product, according to William Blair.
pharminent
June 25, 2026 (Last updated: June 25, 2026)
BioSpace
The approval of Ionis Pharmaceuticals’ Tryngolza for severe hypertriglyceridemia could spur “substantial growth” for the product, according to William Blair.
